menu
    • menu

    Company profile for Oncomatryx

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel prop...
    Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncomatryxSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Parque Tecnológico de Bizkaia 801B – 2P 48160 Derio. Bizkaia
    Telephone
    Telephone
    +34 946 087 037
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncomatryx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncomatryx-biopharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncomatryx Biopharma gets €12.5M EIC Accelerator funding for ADCs
    Oncomatryx Biopharma gets €12.5M EIC Accelerator funding for ADCs

    15 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714824125/en/Oncomatryx-Biopharma-Awarded-%E2%82%AC12.5-Million-EIC-Accelerator-Funding-to-Advance-Groundbreaking-ADCs

    BUSINESSWIRE
    15 Jul 2025
    Share Share
    TFS HealthScience and Oncomatryx Collaborate on OMTX705 Trial
    TFS HealthScience and Oncomatryx Collaborate on OMTX705 Trial

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tfs-healthscience-expands-collaboration-with-oncomatryx-for-phase-ib-trial-of-omtx705-for-pancreatic-cancer-302446072.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Oncomatryx Raises €25 Million to Foster OMTX705 Clinical Trials
    Oncomatryx Raises €25 Million to Foster OMTX705 Clinical Trials

    27 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250127438083/en

    BUSINESSWIRE
    27 Jan 2025
    Share Share
    Oncomatryx acquires Tube Pharma to consolidate its pioneering pipeline
    Oncomatryx acquires Tube Pharma to consolidate its pioneering pipeline

    18 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230518005481/en

    BUSINESSWIRE
    18 May 2023
    Share Share
    Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705 in Solid Tumors
    Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705 in Solid Tumors

    31 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220524005142/en

    BUSINESSWIRE
    31 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search